Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 13–24 of 202 trials
Not yet recruitingAL (light chain)
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis (opens on ClinicalTrials.gov)
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Regeneron Pharmaceuticals
No study locations listed yet
NCT07901725Updated 28 October 2026
Not yet recruitingAL (light chain)
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement (opens on ClinicalTrials.gov)
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid…
- Study
- Interventional (treatment)
- Phase
- Early phase 1
- Sponsor
- Stanford University
Recruiting in: United States
NCT07615270Updated 27 October 2026
RecruitingNot specified
Prevalence of Amyloidosis in Trauma Patients (opens on ClinicalTrials.gov)
This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.
- Study
- Observational (registry, imaging)
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Recruiting in: Spain
NCT06527521Updated 27 October 2026
Not yet recruitingATTR (transthyretin)
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor (opens on ClinicalTrials.gov)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This…
- Study
- Observational (registry, imaging)
- Sponsor
- Bayer
Recruiting in: AustriaGermanyItaly
NCT07557147Updated 26 October 2026
Not yet recruitingATTR (transthyretin)
Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis (opens on ClinicalTrials.gov)
The goal of this clinical trial is to learn if trimetazidine can improve blood flow in the heart in adults with transthyretin cardiac amyloidosis…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Fábio Fernandes
Recruiting in: Brazil
NCT07836699Updated 23 October 2026
Not yet recruitingATTR (transthyretin)
PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels (opens on ClinicalTrials.gov)
The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA) in patients whose standard…
- Study
- Observational (registry, imaging)
- Sponsor
- Lorena Saelices
Recruiting in: United States
NCT07538518Updated 22 October 2026
Enrolling by invitationATTR (transthyretin)
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (opens on ClinicalTrials.gov)
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: ArgentinaAustriaBelgiumBrazil+13
NCT06679946Updated 21 October 2026
RecruitingATTR (transthyretin)
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (opens on ClinicalTrials.gov)
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Novo Nordisk A/S
Recruiting in: ArgentinaAustraliaBelgiumBrazil+16
NCT07207811Updated 21 October 2026
Not yet recruitingAL (light chain)
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis (opens on ClinicalTrials.gov)
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Hadassah Medical Organization
Recruiting in: Israel
NCT07874334Updated 20 October 2026
RecruitingATTR (transthyretin)
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (opens on ClinicalTrials.gov)
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: ArgentinaAustraliaAustriaBelgium+32
NCT07052903Updated 20 October 2026
RecruitingATTR (transthyretin)
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis (opens on ClinicalTrials.gov)
Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this…
- Study
- Interventional (treatment)
- Phase
- Phase 4
- Sponsor
- Bayer
Recruiting in: AustriaBelgiumGermanyItaly+1
NCT07298044Updated 15 October 2026
RecruitingATTR (transthyretin)
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (opens on ClinicalTrials.gov)
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients *…
- Study
- Observational (registry, imaging)
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: BrazilBulgariaDenmarkFrance+8
NCT04561518Updated 13 October 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 7 November 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.